title: Response to "Do metastasis-free interval less or more than 24 months for recurrent metastatic breast cancer and primary surgery for de novo metastatic breast cancer matter for survival?"
authors.affiliation: Department of Medical Oncology, BC Cancer Agency, 600 West 10th Avenue, Vancouver, BC, V5Z 4E6, Canada. wdenbrok@bccancer.bc.ca.
authors.forename: Wendie D
authors.initials: WD
authors.lastname: den Brok
authors.affiliation: Department of Medical Oncology, BC Cancer Agency, 600 West 10th Avenue, Vancouver, BC, V5Z 4E6, Canada.
authors.forename: Caroline H
authors.initials: CH
authors.lastname: Speers
authors.affiliation: Department of Medical Oncology, BC Cancer Agency, 600 West 10th Avenue, Vancouver, BC, V5Z 4E6, Canada.
authors.forename: Lovedeep
authors.initials: L
authors.lastname: Gondara
authors.affiliation: Department of Medical Oncology, BC Cancer Agency, 600 West 10th Avenue, Vancouver, BC, V5Z 4E6, Canada.
authors.forename: Emily
authors.initials: E
authors.lastname: Baxter
authors.affiliation: Department of Radiation Oncology, BC Cancer Agency, Vancouver, BC, Canada.
authors.forename: Scott K
authors.initials: SK
authors.lastname: Tyldesley
authors.affiliation: Department of Medical Oncology, BC Cancer Agency, 600 West 10th Avenue, Vancouver, BC, V5Z 4E6, Canada.
authors.forename: Caroline A
authors.initials: CA
authors.lastname: Lohrisch
mesh_terms: D001943:Breast Neoplasms; D006801:Humans; D009364:Neoplasm Recurrence, Local; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases
chemical_list: D018719:Erb-b2 Receptor Tyrosine Kinases